Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124325432 | 12432543 | 2 | F | 20160630 | 20160603 | 20160715 | EXP | JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2016RR-117803 | RANBAXY | HIRANO A, KODA K, SUZUKI M, YAMAZAKI M, TEZUKA T, KOSUGI C, ET AL. EVALUATION OF MODIFIED OPTIMOX1 PLUS BEVACIZUMAB AS THE NEOADJUVANT THERAPY FOR HIGHLY ADVANCED RECTAL CANCERS. GAN-TO-KAGAKU-RYOHO. 2012;39 (7):1087-1091 | 50.00 | YR | F | Y | 0.00000 | 20160715 | OT | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124325432 | 12432543 | 1 | SS | Calcium folinat | LEUCOVORIN CALCIUM | 1 | Parenteral | 200 MG/M2/2 HOURS, CYCLICAL | U | U | 0 | 200 | MG/M**2 | ||||||
| 124325432 | 12432543 | 2 | SS | 5-Fluorouracil | FLUOROURACIL | 1 | Parenteral | 400 MG/M2/BOLUS, CYCLICAL | U | U | 0 | 400 | MG/M**2 | ||||||
| 124325432 | 12432543 | 3 | SS | 5-Fluorouracil | FLUOROURACIL | 1 | Parenteral | 2400 MG/M2/46 HOURS, UNK | U | U | 0 | 2400 | MG/M**2 | ||||||
| 124325432 | 12432543 | 4 | PS | OXALIPLATIN. | OXALIPLATIN | 1 | Parenteral | 85 MG/M2/2 HOURS, CYCLICAL | U | U | 202922 | 85 | MG/M**2 | ||||||
| 124325432 | 12432543 | 5 | SS | Bevacizumab | BEVACIZUMAB | 1 | Parenteral | 5 MG/KG/30MIN, CYCLICAL | U | U | 0 | 5 | MG/KG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124325432 | 12432543 | 1 | Rectal cancer |
| 124325432 | 12432543 | 2 | Rectal cancer |
| 124325432 | 12432543 | 3 | Rectal cancer |
| 124325432 | 12432543 | 4 | Rectal cancer |
| 124325432 | 12432543 | 5 | Rectal cancer |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 124325432 | 12432543 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124325432 | 12432543 | Disease progression | |
| 124325432 | 12432543 | Female genital tract fistula | |
| 124325432 | 12432543 | Neurotoxicity |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |